Home/ Stocks/ ELTX

Elicio Therapeutics, Inc. Common Stock

ELTX XNAS

$3.19 -0.01 (-0.43%) ▼ 15-min delayed

Open

$3.20

High

$3.27

Low

$3.13

Volume

122.3K

Market Cap

$82.47M

About Elicio Therapeutics, Inc. Common Stock

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 33 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-11,823,000	$-0.65
FY 2025	$0	$-39,571,000	$-2.58
Q3 2025	$0	$-10,083,000	$-0.60
Q2 2025	$0	$-10,561,000	$-0.66

Related Market News

No specific coverage for ELTX yet. Check out our latest market news or earnings calendar.

Get ELTX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Elicio Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.